BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2017 8:51:55 AM | Browse: 340 | Download: 243
Publication Name World Journal of Gastroenterology
Manuscript ID 33459
Country/Territory United States
2017-02-09 08:54
Peer-Review Started
2017-02-09 16:07
To Make the First Decision
2017-04-21 08:28
Return for Revision
2017-04-24 16:22
2017-05-09 02:39
Second Decision
2017-06-12 05:55
Accepted by Journal Editor-in-Chief
2017-06-12 09:21
Accepted by Company Editor-in-Chief
2017-06-19 09:08
Articles in Press
2017-06-19 09:08
Publication Fee Transferred
2017-07-26 03:34
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-09-04 03:10
Publish the Manuscript Online
2017-09-07 08:51
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
Manuscript Source Unsolicited Manuscript
All Author List Al B Benson III, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary and Elya Papoyan
Funding Agency and Grant Number
Funding Agency Grant Number
Novartis Pharmaceuticals, One Health Plaza, East Hanover NJ 07936-1080
Corresponding author Michael S Broder, MD, MHSc, Partnership for Health Analytic Research, LLC, 280 S. Beverly Drive, Suite 404, Beverly Hills, CA90212, United States. mbroder@pharllc.com
Keywords Gastrointestinal neuroendocrine tumors; Treatment patterns; Insurance claims; Somatostatin analogue; Targeted therapy; Chemotherapy
Core Tip In this retrospective study of real-world treatment patterns, somatostatin analogues were the most common initial pharmacologic treatment in patients with gastrointestinal neuroendocrine tumors, and most of the remaining patients began treatment with chemotherapy. However, despite the many treatment options, over half of the patients discontinued treatments after first line and only less than 10% of patients received any second-line pharmacotherapy. Given limitations of claims data to elucidate reasons for this lack of continued treatment, a study using more detailed clinical information such as medical charts or physician surveys is warranted.
Publish Date 2017-09-07 08:51
Citation Benson III AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World J Gastroenterol 2017; 23(33): 6128-6136
Url http://www.wjgnet.com/1007-9327/full/v23/i33/6128.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i33.6128
Full Article (PDF) WJG-23-6128.pdf
Full Article (Word) WJG-23-6128.doc
Manuscript File 33459-Review.docx
Answering Reviewers 33459-Answering reviewers.pdf
Audio Core Tip 33459-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 33459-Conflict-of-interest statement.pdf
Copyright License Agreement 33459-Copyright assignment.pdf
Data Sharing Statement 33459-Data sharing statement.pdf
Signed Informed Consent Form(s) or Document(s) 33459_WJG Informed Consent GI NET Tx Patterns.pdf
Institutional Review Board Approval Form or Document 33459-Institutional review board statement.pdf
Peer-review Report 33459-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 33459-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 33459-Scientific misconduct check.pdf
Scientific Editor Work List 33459-Scientific editor work list.pdf